Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam (NASDAQ: BEAT) reported second quarter 2026 results marked by clinical, commercial, and financial milestones. The company completed enrollment of 134 patients in its ALIGN-ACS heart attack detection pilot study ahead of schedule and surpassed 50% enrollment in the 500-patient Indonesian HEADSTART-ACS study, with full ALIGN-ACS results planned for TCT 2026.
HeartBeam finalized a working prototype of its 12-lead ECG extended wear patch and began a 50-patient pilot study, while advancing the initial commercial launch of the HeartBeam System for arrhythmia assessment, signing multiple agreements across four U.S. regions and shipping first orders. Q2 2026 operating expenses were $5.1 million and net loss was $5.0 million. Cash and cash equivalents rose to $8.7 million as of June 30, 2026, supported by an April public offering raising $11.5 million. The company lowered expected full-year 2026 net operating cash outflow to below $14.0 million, extending cash runway further into 2027.
HeartBeam (NASDAQ: BEAT) will host a conference call on Thursday, August 13, 2026 at 4:30 p.m. Eastern time to discuss second quarter 2026 results and provide updates on its ambulatory ECG signal platform strategy. A detailed earnings release will be issued before the call.
Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and CFO Timothy Cruickshank will lead the call, with Q&A and an accompanying presentation available via webcast and later on the investor relations site. HeartBeam highlights its FDA-cleared 3D, cable-free ECG technology and over 25 issued patents.
HeartBeam (NASDAQ: BEAT) announced allowance of a new U.S. patent that extends its credit card-sized, cable-free ECG device with acoustic sensing and thoracic impedance capabilities. The patent covers integrating acoustic sensors into the device’s foldable arms to act as a “digital stethoscope” for assessing heart valve function, and adding thoracic impedance measurement via finger and chest electrodes to help detect fluid accumulation relevant to heart failure monitoring, without changing the form factor.
According to HeartBeam, this strengthens its multi-modal ambulatory cardiac sensing platform and brings its global portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications, and hardware across the HeartBeam System and its investigational on-demand 12-lead patch.
HeartBeam (NASDAQ: BEAT) completed enrollment ahead of schedule in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The study enrolled 120 chest-pain patients across two Serbia sites. Data analysis is underway and results are expected at an upcoming cardiology conference, guiding a planned U.S. pivotal study and a potential FDA submission to expand the system’s indication from arrhythmia to heart attack assessment.
HeartBeam (NASDAQ: BEAT) announced a strategic shift to license its 3D ambulatory ECG signal platform to established partners instead of focusing on direct device sales. A company-wide reorganization aims to enhance global reach, accelerate execution, and create a leaner cost structure, alongside a leadership transition as former CEO Robert Eno moves to a consulting role.
The strategy targets expansion from arrhythmia assessment into heart attack detection, adapts the platform to multiple form factors and channels, and builds on FDA clearance received in December 2025 for its synthesized 12-lead ECG signal for arrhythmia assessment.
HeartBeam (NASDAQ: BEAT) announced a peer-reviewed JACC: Advances article on a proof-of-concept risk prediction algorithm that combines its portable ECG device with patient risk factors and symptoms to identify heart attack risk in chest-pain patients.
The study in 184 analyzed patients reported AUCs of 86.5% with a single ECG and 92.9% when a personal baseline ECG was available, and a 19.8% false-positive rate versus 55.6% for a physician panel. Heart attack detection is described as a major potential expansion, targeting over 20 million high-risk U.S. patients and supported by the ALIGN-ACS pilot study enrolling ahead of schedule.
HeartBeam (NASDAQ: BEAT) reported first quarter 2026 results and key milestones in its cardiac care platform.
The company signed first commercial partnerships with ClearCardio and Atelier Health, launched flagship sites in New York, Dallas, South Florida and Southern California, and advanced heart attack detection and 12-lead ECG patch pilot studies.
HeartBeam reported Q1 2026 R&D expenses of $2.4M, SG&A of $2.3M, and a net loss of $4.7M, with operating cash use down 19% year over year.
Cash was $2.0M on March 31, 2026, and an April 2026 equity offering raised $11.5M in gross proceeds.
HeartBeam (NASDAQ: BEAT) began a pilot study of its investigational on-demand 12-lead ECG patch in patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia.
The ~50-patient study compares a synthesized 12-lead ECG from the patch with a standard 12-lead ECG after exercise stress testing, targeting an ambulatory patch ECG market of about $2 billion with established reimbursement.
HeartBeam (NASDAQ: BEAT) announced a commercial agreement with Beverly Hills-based Atelier Health, expanding its initial launch footprint to four U.S. markets: New York metro, Dallas, South Florida, and Southern California.
The partnership adds a concierge practice led by physicians affiliated with Cedars-Sinai and furthers HeartBeam’s subscription-based commercialization approach and cable-free 3D ECG placement for home clinical-grade 12-lead synthesis.
HeartBeam (NASDAQ: BEAT) will host a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern to review first-quarter results for the period ended March 31, 2026 and provide updates on strategic initiatives.
Management will discuss a limited commercial launch for arrhythmia assessment, progress on an extended-wear patch, heart attack detection work, and AI initiatives. A press release will be issued before the call; a presentation and webcast will be available via the company investor relations site.